"uuid:ID","versionIdentifier","instanceType","rationale","id"
"ff1e240c-df82-4c27-950d-015c678f15df","2","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1"
